Y Natkunam

Summary

Publications

  1. pmc Immunoblot analysis of CD34 expression in histologically diverse neoplasms
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, Stanford, California 94305, USA
    Am J Pathol 156:21-7. 2000
  2. ncbi Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, Stanford, California 94305, USA
    Mod Pathol 14:686-94. 2001
  3. ncbi Angiocentric lymphomas (lymphomatous vasculitis)
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, CA 94305, USA
    Semin Diagn Pathol 18:67-77. 2001
  4. ncbi Natural killer cell precursor acute lymphoma/leukemia presenting in an infant
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, Calif 94305, USA
    Arch Pathol Lab Med 125:413-8. 2001
  5. ncbi Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, CA 94305, USA
    J Cutan Pathol 27:392-9. 2000
  6. ncbi Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course
    S Mraz-Gernhard
    Departments of Dermatology, Pathology, and Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Oncol 19:2179-88. 2001
  7. ncbi A unique AML1 (CBF2A) rearrangement, t(1;21)(p32;q22), observed in a patient with acute myelomonocytic leukemia
    A M Cherry
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Cancer Genet Cytogenet 129:155-60. 2001
  8. ncbi Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Clin Lymphoma 2:185-7. 2001
  9. ncbi Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma
    I S Lossos
    Department of Medicine, Division of Oncology, Stanford University Medical Center, CA 94305-5151, USA
    Blood 98:945-51. 2001
  10. ncbi Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder
    O Hatton
    Program in Immunology, Department of Surgery Division of Abdominal Transplantation, Stanford University School of Medicine, Stanford, CA, USA
    Am J Transplant 13:883-90. 2013

Collaborators

Detail Information

Publications10

  1. pmc Immunoblot analysis of CD34 expression in histologically diverse neoplasms
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, Stanford, California 94305, USA
    Am J Pathol 156:21-7. 2000
    ..These results show that the observed immunohistological reactivity with anti-CD34 antibodies is due to the expression of the CD34 protein and not to shared epitopes on unrelated proteins...
  2. ncbi Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, Stanford, California 94305, USA
    Mod Pathol 14:686-94. 2001
    ....
  3. ncbi Angiocentric lymphomas (lymphomatous vasculitis)
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, CA 94305, USA
    Semin Diagn Pathol 18:67-77. 2001
    ..The salient clinicopathologic features of natural killer and natural killer-like T-cell lymphomas together with the inherent difficulty of their identification and an integrated approach to their diagnosis are outlined in this article...
  4. ncbi Natural killer cell precursor acute lymphoma/leukemia presenting in an infant
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, Calif 94305, USA
    Arch Pathol Lab Med 125:413-8. 2001
    ..This case emphasizes the need for a strong index of suspicion to recognize this rare entity and to distinguish it from solid tumors and other hematolymphoid neoplasms that occur in infancy...
  5. ncbi Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, CA 94305, USA
    J Cutan Pathol 27:392-9. 2000
    ..Lymphomas with co-expression of CD56 and CD30 are extremely rare and the significance of this co-expression is unknown...
  6. ncbi Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course
    S Mraz-Gernhard
    Departments of Dermatology, Pathology, and Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Oncol 19:2179-88. 2001
    ..To describe and identify the clinical and pathologic features of prognostic significance for natural killer (NK) and NK-like T-cell (NK/T-cell) lymphoma presenting in the skin...
  7. ncbi A unique AML1 (CBF2A) rearrangement, t(1;21)(p32;q22), observed in a patient with acute myelomonocytic leukemia
    A M Cherry
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Cancer Genet Cytogenet 129:155-60. 2001
    ..Here, we describe a patient with AML-M4 and a previously unreported rearrangement involving the AML1 locus and an unknown locus on the short arm of chromosome 1 at 1p32...
  8. ncbi Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab
    Y Natkunam
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Clin Lymphoma 2:185-7. 2001
    ..We present an unusual case of a 30-year-old man with recurrent TCRBCL arising from lymphocyte-predominant Hodgkin's disease with remarkable response to treatment with the anti-CD20 antibody, rituximab...
  9. ncbi Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma
    I S Lossos
    Department of Medicine, Division of Oncology, Stanford University Medical Center, CA 94305-5151, USA
    Blood 98:945-51. 2001
    ..High BCL-6 mRNA expression should be considered a new favorable prognostic factor in DLBCL and should be used in the stratification and the design of risk-adjusted therapies for patients with DLBCL. (Blood. 2001;98:945-951)..
  10. ncbi Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder
    O Hatton
    Program in Immunology, Department of Surgery Division of Abdominal Transplantation, Stanford University School of Medicine, Stanford, CA, USA
    Am J Transplant 13:883-90. 2013
    ..Taken together, our data indicate that Syk activates PI3K/Akt signaling which is required for survival of EBV+ B cell lymphomas. PI3K/Akt signaling may be a promising therapeutic target for PTLD, and other EBV-associated malignancies...